MedImmune Recalls 4.7 Million Doses of H1N1 Vaccine Because of Drop in Potency
MedImmune, a division of AstraZeneca (London, UK), yesterday recalled 13 lots (4.7 million doses) of its nasal spray H1N1 (swine) flu vaccine, because of a drop in potency.
MedImmune, a division of AstraZeneca (London, UK), yesterday recalled 13 lots (4.7 million doses) of its nasal spray H1N1 (swine) flu vaccine, because of a drop in potency.
The company detected the slight decline in potency as part of its routine stability testing, and notified the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration on December 16 and 21. The vaccine in these lots is still expected to be effective in stimulating immunity, however, so people who received vaccinations from those lots do not need to be re-vaccinated.
Most of the affected doses were shipped in the first few weeks of H1N1 vaccination, when the vaccine's potency was still at or above the specification limit.
Sanofi-Aventis SA (Paris, France) recalled 800,000 doses of its pediatric H1N1 flu vaccine on December 15, also because of a drop in potency detected during stability studies.
Previous coverage:
Sanofi Recalls 800,000 Doses of H1N1 (Swine) Flu Vaccine for Children
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
